A new American study from the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases has shown the effectiveness of three different antibodies against the Human Immunodeficiency Virus (HIV), providing independent protection against the virus in experiments conducted on monkeys.

• Anxiety and sleep disturbances: New symptoms for Coronavirus Variant “JN.1” 

The targeted antibodies, including the broadly neutralizing human antibody and two antibodies isolated from previously immunized monkeys, aim at the fusion peptide. This peptide is a region on the surface protein of the HIV virus that facilitates its entry into cells.

• A “unprecedented” virus infects a young man in Peru

The study, published in “Science Translational Medicine,” involved intravenous injections of these antibodies in rhesus macaque monkeys. The monkeys that received the antibodies showed significant protection, with varying levels of effectiveness.

• “Vampire” virus leaves scientists 

The study suggests evidence for the preventive potential of fusion peptide-targeted antibodies and emphasizes the need to generate diverse antibodies in designing an effective vaccine for the Human Immunodeficiency Virus targeting the fusion peptide.